Archive: December 27 2020

Find relevant news articles from other European projects, below:

CARAMBA  EURE-CART  CARAT Network ATECT PROCROP T2EVOLVE

Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:


Immunotherapy Web Featured Images 70

CARTITUDE-1 study: Are responses with cilta-cel deep and durable?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Deepu Madduri, Icahn School of Medicine at Mount Sinai, New York, US, about the CARTITUDE-1 study. We asked, Are responses with ciltacabtagene autoleucel (cilta-cel) deep and durable? Madduri discusses the preliminary data from the CARTITUDE-1 study evaluating cilta-cel in patients with relapsed/refractory multiple myeloma.

Visit website